Gilead takes a hit af­ter a close­ly-watched Covid-19 tri­al of remde­sivir is qui­et­ly ter­mi­nat­ed, rais­ing fresh doubts

Shares of Gilead took a 3% hit $GILD Wednes­day af­ter re­searchers not­ed that they had sus­pend­ed one of the close­ly-watched Covid-19 stud­ies for remde­sivir in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.